BACKGROUND: Demonstration of clinical benefits on disability progression measures is an important attribute of effective multiple sclerosis (MS) treatments. OBJECTIVE: Examine efficacy of daclizumab beta versus intramuscular (IM) interferon beta-1a on measures of disability progression in patient subgroups from DECIDE. METHODS: Twenty-four-week confirmed disability progression (CDP), 24-week sustained worsening on a modified Multiple Sclerosis Functional Composite (MSFCS) where 3-Second Paced Auditory Serial Addition Test was replaced by Symbol Digit Modalities Test, and proportion of patients with clinically meaningful worsening in 29-Item Multiple Sclerosis Impact Scale physical impact subscale (MSIS-29 PHYS) score from baseline to week 96 were examined in the overall population and subgroups defined by baseline demographic/disease characteristics. RESULTS: Daclizumab beta significantly reduced risk of 24-week CDP (hazard ratio (HR), 0.73; 95% confidence interval (95% CI), 0.55-0.98), risk of 24-week sustained MSFCS progression (HR, 0.80; 95% CI, 0.67-0.95), and odds of clinically meaningful worsening in MSIS-29 PHYS (odds ratio, 0.76; 95% CI, 0.60-0.95) versus IM interferon beta-1a. Point estimates showed trends favoring daclizumab beta over IM interferon beta-1a across several patient subgroups for all three outcome measures. CONCLUSION: Daclizumab beta showed consistent benefit versus IM interferon beta-1a across measures assessing patient disability/function and across a range of clinical baseline characteristics in patients with relapsing-remitting MS.

AbbVie Inc North Chicago IL USA

Biogen Cambridge MA USA

Blizard Institute Barts and The London School of Medicine and Dentistry Queen Mary University London London UK

Department of Neurology and Center for Clinical Neuroscience 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Neurology Medical University of Lodz Lodz Poland

Department of Neurology University of Münster Münster Germany

Department of Neurology University of Utah and Neurovirology Research Laboratory VASLCHCS Imaging and Neuroscience Center Salt Lake City UT USA

Neurologic Clinic and Policlinic Departments of Medicine Clinical Research and Biomedical Engineering University Hospital and University of Basel Basel Switzerland

Providence Multiple Sclerosis Center Providence Brain and Spine Institute Providence St Joseph Health Portland OR USA

Zobrazit více v PubMed

Ebers GC, Heigenhauser L, Daumer M, et al. Disability as an outcome in MS clinical trials. Neurology 2008; 71: 624–631. PubMed

Wiendl H, Meuth SG. Pharmacological approaches to delaying disability progression in patients with multiple sclerosis. Drugs 2015; 75: 947–977. PubMed PMC

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452. PubMed

Lavery AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting multiple sclerosis: Capturing disability and disease progression in clinical trials. Mult Scler Int 2014; 2014: 262350. PubMed PMC

Balcer LJ. Clinical outcome measures for research in multiple sclerosis. J Neuroophthalmol 2001; 21: 296–301. PubMed

Cohen JA, Reingold SC, Polman CH, et al. Disability outcome measures in multiple sclerosis clinical trials: Current status and future prospects. Lancet Neurol 2012; 11: 467–476. PubMed

Polman CH, Rudick RA. The multiple sclerosis functional composite: A clinically meaningful measure of disability. Neurology 2010; 74(Suppl. 3): S8–S15. PubMed

Rudick RA, Polman CH, Cohen JA, et al. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 2009; 15: 984–997. PubMed

Drake AS, Weinstock-Guttman B, Morrow SA, et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: Replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler 2010; 16: 228–237. PubMed

Lopez-Gongora M, Querol L, Escartin A. A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: An appraisal of comparative longitudinal sensitivity. BMC Neurol 2015; 15: 40. PubMed PMC

Strober LB, Rao SM, Lee JC, et al. Cognitive impairment in multiple sclerosis: An 18 year follow-up study. Mult Scler Relat Disord 2014; 3: 473–481. PubMed

Cohen JA, Cutter GR, Fischer JS, et al. Use of the Multiple Sclerosis Functional Composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001; 58: 961–967. PubMed

Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2015; 373: 1418–1428. PubMed

Liu Y, Vollmer T, Havrdova E, et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2017; 11: 18–24. PubMed

Rudick RA. MS clinical trials: What can subgroup analyses teach us? Lancet Neurol 2012; 11: 386–388. PubMed

Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of Multiple Sclerosis Lesions: Implications for the Pathogenesis of Demyelination. Ann Neurol 2000; 47: 707–717. PubMed

International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline: Guideline for good clinical practice, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (1996, accessed 2 February 2015).

Kappos L. Definitions for a standardised, quantified neurological examination and assessment of Kurtzke’s Functional Systems and Expanded Disability Status Scale in Multiple Sclerosis, https://www.neurostatus.net/media/specimen/Definitions_0309_specimen.pdf (2009, accessed 4 May 2017).

Benedict RH, Morrow S, Rodgers J, et al. Characterizing cognitive function during relapse in multiple sclerosis. Mult Scler 2014; 20: 1745–1752. PubMed

Phillips GA, Wyrwich KW, Guo S, et al. Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening. Mult Scler 2014; 20: 1753–1760. PubMed PMC

Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons, 1987.

Karabudak R, Dahdaleh M, Aljumah M, et al. Functional clinical outcomes in multiple sclerosis: Current status and future prospects. Mult Scler Relat Disord 2015; 4: 192–201. PubMed

European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500185161.pdf (2015, accessed 16 September 2016).

Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain 2001; 124: 962–973. PubMed

Costelloe L, O’Rourke K, McGuigan C, et al. The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite. Mult Scler 2008; 14: 255–258. PubMed

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01064401